Gilead is teaming up with Vir on solid tumor cancer drugs in a deal worth up to $1.9 billion
Source ↗
👁 0
💬 0
Vir Biotechnology will receive $90 million upfront and could earn up to $1.74 billion in later milestone payments
Comments (0)